Abstract
Dermatomyositis was first described in the late nineteenth century by Ernst Wagner, and detailed descriptions of clinical course and skin disease by German physician Heinrich Unverricht led to its distinction from polymyositis. This leads to the rarely used eponym “Wagner-Unverricht syndrome.” Later discoveries included malignancy association (1916), details of cutaneous manifestations by Gottron (1930), differentiation from systemic lupus erythematosus (1942), and amyopathic dermatomyositis (1975). The first full postmortem examination of a child with dermatomyositis was published in 1912. Childhood cases represented 20 % of 338 cases reviewed in two large case series in the presteroid era in 1932 and 1939, although the differences between and childhood and adult dermatomyositis didn’t become clear until 1966.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Wagner E. Fall einer seltnen Muskelkrankheit. Dtsch Arch Heilk. 1863;4:282–3.
Unverricht H. Dermatomyositis acuta. Dtsch Med Wochenschr. 1891;17:41–4.
Stertz G. Polymyositis. Berl Klin Wochenshr. 1916;53:489.
Kankeleit H. Über primaire nichteitrige Polymyositis. Dtsch Arch Klin Med. 1916;120:335–9.
Gottron H. Hautveränderungen bei Dermatomyositis. VIII Congres Intern. Dermatol. et Syphilogr., Copenhagen, 5–8 Agout, 1930, Compt rend Seancy, Ed. S.Lomholt, Copenhagen 1931; 826–830.
Keil H. The manifestations in the skin and mucus membranes in dermatomyositis with special reference to the differential diagnosis from systemic lupus erythematosus. Ann Intern Med. 1942;16:827.
Krain LS. Dermatomyositis in six patients without initial muscle involvement. Arch Dermatol. 1975;111:241–6.
Batten FE. Case of dermatomyositis in a child, with pathological report. Br J Child Dis. 1912;9:247.
Karelitz S, Welt SK. Dermatomyositis. Am J Dis Child. 1932;43:1134.
Scheuermann H. Zur klinik und pathogenese der dermatomyositis (polymyositis). Arch Dermal u syph. 1939;178:414.
Banker BQ, Victor M. Dermatomyositis (systemic angiography) of childhood. Medicine. 1966;45:261.
Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med. 1975;292:344–7.
Bendewald MJ, et al. Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County, Minnesota. Arch Dermatol. 2010;146(1):26–30.
Plotz PH, Dalakas M, Leff RL, et al. Current concepts in the idiopathic inflammatory myopathies: polymyositis, dermatomyositis, and related disorders. Ann Intern Med. 1989;111:143–57.
Kissel JT, Mendell JR, Rammohan KW. Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med. 1986;314(6):329–34.
Bohan A, et al. Computer-assisted analysis of 153 cases patients with polymyositis and dermatomyositis. Medicine (Baltimore). 1977;56:255.
Dalakas MC, Hohlbeld R. Polymyositis and dermatomyositis. Lancet. 2003;362(9388):971–80.
Lundberg IE. The heart and dermatomyositis and polymyositis. Rheumatology. 2006;45:iv18–21.
Caro I. Dermatomyositis as a systemic disease. Med Clin North Am. 1989;73:1181–92.
Marie I, Hachulla E, Cherin P, Dominique S, Hatron PY, Hellot MF, Devulder B, Herson S, Levesque H, Courtois H. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum. 2002;47:614–22.
Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Fujita T, Kuwana M. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum. 2009;60(7):2193–200.
Sato S, Kuwana M, Fujita T, Suzuki Y. Amyopathic dermatomyositis developing rapidly progressive interstitial lung disease with elevation of anti-CADM-140/MDA5 antibodies. Mod Rheumatol. 2012;22(4):625–9.
Crowe WE, Bove KE, Levinson JE, et al. Clinical and pathogenetic implications of histopathology in childhood polydermatomyositis. Arthritis Rheum. 1982;25:126–39.
Tansley SL, McHugh NJ, Wedderburn LR. Adult and juvenile dermatomyositis: are the distinct clinical features explained by our current understanding of serologic subgroups and pathogenic mechanisms? Arth Res Ther. 2013;15:211.
Cox NH, Lawrense CM, Langtry JAA, et al. Dermatomyositis. Disease associations and an evaluation of screening investigations for malignancy. Arch Dermatol. 1990;126:61–5.
Buchbinder R, Forbes A, Hall S, Dennett X, Giles G. Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Intern Med. 2001;134:1087–95.
Kasper CS, White CL, Freeman RG. Pathology and immunopathology of polymyositis and dermatomyositis. Clin Dermatol. 1988;6:64–75.
Bowyer SL, Clark RA, Ragsdale CG, et al. Juvenile dermatomyositis: histologic findings and pathogenetic hypothesis for the associated skin change. J Rheumatol. 1986;13:753–9.
Dawkins MA, Jorizzo JL, Walker FO, Albertson D, Sinal SH, Hinds A. Dermatomyositis: a dermatology-based case series. J Am Acad Dermatool. 1998;38:397–404.
Vencovsky J, Jarosova K, Machacek S, Studynkova J, Kafkova J, Bartunkova J, et al. Cyclosporine a versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol. 2000;29:95–102.
Joffe MM, Love LA, Leff RL, Fraser DD, Targoff IN, Hicks JE, et al. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med. 1993;94:379–87.
Miller J, Walsh Y, Saminaden S, Lecky BRF, Winer JB. Randomized double blind trial of methotrexate and steroids compared with azathioprine and steroids in the treatment of idiopathic inflammatory myopathy. J Neurol Sci. 2002;199(Suppl):S53.
Drake LA, Dinehart SM, Farmer ER, Goltz RW, Graham GF, Hordinsky MK, et al. Guidelines of care for dermatomyositis: American Academy of Dermatology. J Am Acad Dermatol. 1996;34:824–9.
Iorizzo LJ, Jorizzo JL. The treatment and prognosis of dermatomyositis: an updated review. J Am Acad Dermatol. 2008;59(1):99–112.
Gelber AC, Nousari HC, Wigley FM. Mycophenolate Mofetil in the treatment of severe skin manifestations of dermatomyositis: a series of 4 cases. J Rheumatol. 2000;27:1542–5.
Kasteler JS, Callen JP. Low-dose methotrexate administered weekly is an effective corticosteroid-sparing agent for the treatment of the cutaneous manifestations of dermatomyositis. J Am Acad Dermatol. 1997;36:67–71.
Crowe WE. Dermatomyositis and polymyositis. In: Gershwin ME, Robbins DL, editors. Musculoskeletal diseases of children. New York: Grune & Stratton; 1983. p. 113–37.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Crowe, D.R. (2016). Dermatomyositis. In: Crowe, D., Morgan, M., Somach, S., Trapp, K. (eds) Deadly Dermatologic Diseases. Springer, Cham. https://doi.org/10.1007/978-3-319-31566-9_36
Download citation
DOI: https://doi.org/10.1007/978-3-319-31566-9_36
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-31564-5
Online ISBN: 978-3-319-31566-9
eBook Packages: MedicineMedicine (R0)